drugset / Trial / NCT00457678
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.
Timeline
- Start
- 2007-01
- Primary completion
- 2007-12-04
- Completion
- 2007-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.5 mg | — |
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Verteporfin | Other / unclassified | — | — |